What are the economic implications of Heart Failure?
The economic burden of Heart Failure is substantial and is expected to increase markedly in parallel with increases in HF prevalence. Between 2012 and 2030, total direct medical costs for HF are projected to increase from $21 billion to $53 billion (141), while total costs (including indirect outlay) are estimated to increase from $30.7 billion to $69.8 billion (5). After hospital costs, the cost of cardiovascular medications is the second most important cost for patients with HF, accounting for 15.6% of direct costs (142).